Enrollment of 56 patients with male pattern hair loss in the Phase I/II clinical trial of HSC has been completed, and the trial is ongoing. Dr. Gail Naughton, Histogen CEO and Chairman of the Board, presented the 12 week primary safety and efficacy data at the Society for Investigative Dermatology (SID) Annual Meeting on May 11, 2012. The treatment was well-tolerated and no study-related adverse events have been reported. In this second clinical trial of HSC, which was designed with an additional treatment timepoint, the increase in total hair count was 46.5% above that seen in the pilot HSC trial at 12 weeks. Statistical significance was noted in all efficacy endpoints which include increases in total hair count (p=0.0013), terminal hairs (p=0.0135) and hair thickness (p=0.026). A brief on the data presented by Dr. Naughton during the SID Annual Meeting.
http://www.histogen.com/applications/hsc.htm
http://www.histogen.com/applications/hsc.htm
Comment